Abbott Laboratories
ABT.N- Latest Trade
- trading higher97.26USD
- 0.22
- 0.23%
- As of Mar 24 2023. Values delayed up to 15 minutes
- Today's Range
- 96.81 - 97.62
- 52 Week Range
- 93.27 - 124.35
- Previous Close
- 97.04
- Open
- 97.26
- Volume
- 495,200.00
- 3 Month Average Trading Volume
- 100.55
- Shares Out (Mil)
- 1,737.95
- Market Cap
- 168,337.50
- Forward P/E
- 21.99
- Dividend Yield
- 2.11
Key Statistics
2.04 mean rating - 24 analysts
- P/E Excl. Extra Items (TTM)
- 24.68
- Price To Sales (TTM)
- 3.86
- Price To Book (Quarterly)
- 4.59
- Price To Cash Flow (Per Share TTM)
- 16.50
- Total Debt/Total Equity (Quarterly)
- 45.72
- Long Term Debt/Equity (Quarterly)
- 39.58
- Return On Investment (TTM)
- 11.50
- Return On Equity (TTM)
- 9.27
2021 (millions USD)
About Abbott Laboratories (ABT.N)
Company Information
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
Address
100 Abbott Park RdABBOTT PARK, IL
60064-3500
United States
Industry
Medical Equipment & Supplies
Executive Leadership
- Robert B. Ford
- Chairman of the Board, Chief Executive Officer
- Robert E. Funck
- Chief Financial Officer, Executive Vice President - Finance
- Hubert L. Allen
- Executive Vice President, General Counsel, Secretary
- Mary K. Moreland
- Executive Vice President - Human Resources
- John M. Capek
- Executive Vice President - Ventures
- Lisa D. Earnhardt
- Executive Vice President - Medical Devices
- John F. Ginascol
- Executive Vice President - Core Diagnostics
- Daniel Gesua Sive Salvadori
- Executive Vice President - Nutritional Products
- Andrea Wainer
- Executive Vice President - Rapid and Molecular Diagnostics
- Gregory A. Ahlberg
- Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
- Christopher J. Calamari
- Senior Vice President - U.S. Nutrition
- Michael Donald Dale
- Senior Vice President - Structural Heart
- Sammy Karam
- Senior Vice President - Established Pharmaceuticals, Emerging Markets
- Joseph J. Manning
- Senior Vice President - International Nutrition
- Louis H. Morrone
- Senior Vice President - Rapid Diagnostics
- Michael J. Pederson
- Senior Vice President - Electrophysiology
- Jared L. Watkin
- Senior Vice President - Diabetes Care
- Alejandro D. Wellisch
- Senior Vice President - Established Pharmaceuticals, Latin America
- Randel Woodgrift
- Senior Vice President - CRM
- Philip P. Boudreau
- Vice President - Finance, Controller
- William A. Osborn
- Lead Independent Director
- Claire Babineaux-fontenot
- Director
- Robert J. Alpern
- Independent Director
- Sally E. Blount
- Independent Director
- Patricia Paola Gonzalez
- Independent Director
- Michelle A. Kumbier
- Independent Director
- Darren W. McDew
- Independent Director
- Nancy Mckinstry
- Independent Director
- Michael F. Roman
- Independent Director
- Daniel J. Starks
- Independent Director
- John G. Stratton
- Independent Director
- Glenn Fletcher Tilton
- Independent Director
Latest News
- BusinessMedtronic expects inflation to weigh on earnings next fiscal
Medtronic Plc said on Tuesday it expects inflation in various markets to hit its profit in the next fiscal year after the medical device maker beat earnings estimate for the third quarter on strong demand for its heart and diabetes devices.
- BusinessLabcorp forecasts up to 90% fall in COVID testing sales in 2023
Laboratory Corp of America Holdings on Thursday predicted that COVID testing sales could fall by up to 90% this year after nearly two years of a boost to its diagnostics unit during the pandemic.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,985.50 | 0.42% |
| Copper | 785.40 | 0.25% |
| Brent Crude Oil | 74.53 | 1.82% |
| CBOT Soybeans | 1,428.25 | 0.62% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,939.03 | 0.25% |
| Euro STOXX 50 | 4,125.83 | 1.93% |
| FTSE 100 | 7,405.45 | 1.26% |
| Nikkei 225 | 27,385.25 | 0.13% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes